Company / SG&A Expense
Candel Therapeutics, Inc. SG&A Expense History
FY2021-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$13.9M
FY2023
5-year range
$5.2M / $13.9M
FY2021-FY2023
Trend
+30.1%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $5M to $14M over the past 2 years.
Based on SEC 10-K filings.
$14M in FY2023.
Increased from $5M to $14M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2023, sg&a expense increased 30.1% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $13.9M | +30.1% |
| FY2022 | $10.7M | +106.0% |
| FY2021 | $5.2M | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026